Pre-market hot trades in US stocks: Lithium Americas up 9.48% pre-market; Cyclerion Therapeutics down 8.00% pre-market

Pre-market Hot Trades in US Stocks

Lithium Americas is up 9.48% in pre-market trading. Based on recent key news:

1. On September 24, the US government plans to restructure a $2.3 billion Department of Energy loan through equity investment, causing Lithium Americas' stock price to surge 98.7% after hours. This move is seen as a boost in confidence for the company's financing and project advancement.

2. On September 24, the Trump administration sought to hold a 10% stake in Lithium Americas as part of renegotiating the Thacker Pass project loan, significantly driving up the stock price.

3. On September 25, Lithium Americas confirmed ongoing negotiations with the US Department of Energy and General Motors regarding financing terms for the Thacker Pass project, further enhancing market confidence. The lithium industry is supported by policy, leading to increased market volatility.

Cyclerion Therapeutics is down 8.00% in pre-market trading. Based on recent key news:

1. On September 24, Cyclerion Therapeutics announced a licensing agreement with the Massachusetts Institute of Technology, repositioning itself as a neuropsychiatric company. This news drove the stock price up 43% in pre-market trading.

2. On September 23, the company announced that its main project will begin mid-stage trials in 2026, with data expected in 2027. This news further bolstered market confidence.

3. On September 23, an analysis report indicated that Cyclerion Therapeutics has 5 warning signs, 2 of which are concerning, advising investors to be cautious. Industry trends and macro dynamics need close attention.

Top Gainers in Pre-market US Stocks

PepGen is up 91.35% in pre-market trading. Based on recent important news:

1. On September 25, PepGen announced an underwritten public offering at a price of $3.20 per share, expecting to raise $100 million. This move drove the stock price up 119.55% in after-hours trading. Data source: company announcement.

2. On September 24, PepGen released positive clinical data from its FREEDOM-DM1 study for the 15 mg/kg dosage cohort, showing an average splice correction rate of 53.7%. This result boosted market confidence in the company's R&D capabilities. Data source: company announcement.

3. On September 25, Guggenheim reiterated its buy rating on PepGen and maintained a target price of $6, further supporting the stock price increase. Data source: analyst report. The biotechnology industry has shown recent volatility and requires attention